Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camilla Qvortrup

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Acta Oncologica (Stockholm, Sweden)|July 10, 2010
Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancerCamilla Qvortrup, Benny Vittrup Jensen, Trine Lembrecht Jorgensen, et al.
Acta Oncologica (Stockholm, Sweden)|March 19, 2008
Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)Lene W Vestermark, Anders Jacobsen, Camilla Qvortrup, et al.
Cancer|June 30, 2009
Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patientsHalfdan Sorbye, Per Pfeiffer, Nina Cavalli-Björkman, et al.
Ugeskrift for Laeger|February 2, 2024
Henry Jensen, Line Flytkjær Virgilsen, Linda Aagaard Rasmussen, et al.
Acta Oncologica (Stockholm, Sweden)|December 3, 2016
S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studiesPer Pfeiffer, Camilla Qvortrup, Merete Krogh, et al.
Annals of Surgery|January 14, 2025
Association between Deficient MSH2/MSH6 vs MLH1/PMS2 Status and Survival Rates in Localized Colorectal Cancer: A Nationwide Cohort StudyTobias Freyberg Justesen, Adile Orhan, Andreas Weinberger Rosen, et al.
Journal of Geriatric Oncology|September 25, 2024
Dose reduced preoperative chemotherapy in older patients with resectable gastroesophageal cancer: A real-world data studyJosephine Skjoldbirk, Kristian Egebjerg, Camilla Qvortrup, et al.
BMC Cancer|December 16, 2022
A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON studyMartina Eriksen, Per Pfeiffer, Kristoffer Staal Rohrberg, et al.
Lung Cancer (Amsterdam, Netherlands)|March 9, 2025
Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide studyMatilde Grupe Frost, Kristoffer Jarlov Jensen, Espen Jimenez-Solem, et al.
Plos One|August 12, 2017
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancerChristina Siesing, Halfdan Sorbye, Anca Dragomir, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Acta Oncologica (Stockholm, Sweden)|July 10, 2010
Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancerCamilla Qvortrup, Benny Vittrup Jensen, Trine Lembrecht Jorgensen, et al.
Acta Oncologica (Stockholm, Sweden)|March 19, 2008
Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC)Lene W Vestermark, Anders Jacobsen, Camilla Qvortrup, et al.
Cancer|June 30, 2009
Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patientsHalfdan Sorbye, Per Pfeiffer, Nina Cavalli-Björkman, et al.
Ugeskrift for Laeger|February 2, 2024
Henry Jensen, Line Flytkjær Virgilsen, Linda Aagaard Rasmussen, et al.
Acta Oncologica (Stockholm, Sweden)|December 3, 2016
S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studiesPer Pfeiffer, Camilla Qvortrup, Merete Krogh, et al.
Annals of Surgery|January 14, 2025
Association between Deficient MSH2/MSH6 vs MLH1/PMS2 Status and Survival Rates in Localized Colorectal Cancer: A Nationwide Cohort StudyTobias Freyberg Justesen, Adile Orhan, Andreas Weinberger Rosen, et al.
Journal of Geriatric Oncology|September 25, 2024
Dose reduced preoperative chemotherapy in older patients with resectable gastroesophageal cancer: A real-world data studyJosephine Skjoldbirk, Kristian Egebjerg, Camilla Qvortrup, et al.
BMC Cancer|December 16, 2022
A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON studyMartina Eriksen, Per Pfeiffer, Kristoffer Staal Rohrberg, et al.
Lung Cancer (Amsterdam, Netherlands)|March 9, 2025
Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide studyMatilde Grupe Frost, Kristoffer Jarlov Jensen, Espen Jimenez-Solem, et al.
Plos One|August 12, 2017
High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancerChristina Siesing, Halfdan Sorbye, Anca Dragomir, et al.
Pageof 7